Quest Diagnostics is an essential U.S. healthcare infrastructure provider, with its Diagnostic Information Services segment generating approximately 98% of consolidated revenue. Its catalog exceeds 3,500 assays, spanning routine clinical testing and advanced oncology, neurology, genetic, and molecular diagnostics. It serves one in three adult Americans and works with approximately half of U.S. physicians and hospital systems. Nationwide logistics, broad payor coverage, cost scale, and EHR integration support a co-duopoly position with Labcorp and meaningful switching costs. Q2 2026 revenue rose 10.2% to $3.043 billion, with 13.1% requisition growth offset partly by a 2.8% decline in revenue per requisition. Adjusted EPS increased 19.1% to $3.12, beating consensus by $0.30, and management raised 2026 revenue guidance to $11.95–$12.05 billion and adjusted EPS to $11.05–$11.25. At $230.44, DGX trades at about 20.4x FY2026E forward earnings and 12.2x LTM EV/EBITDA, with a 5.3% FCF yield and 1.5% dividend yield. **The investment case is resilient volume compounding plus advanced-test and consumer growth;** near-term catalysts include Q3 results, joint-venture execution, and continued growth in consumer and proprietary assays.

Quest Diagnostics Inc (DGX) Investment Analysis:

1. Executive Summary:

Quest Diagnostics Incorporated (NYSE: DGX) serves as an essential infrastructure provider within the United States healthcare ecosystem [cite: 1, 2]. Operating primarily through its Diagnostic Information Services segment, which generates approximately 98% of consolidated net revenues, the company delivers diagnostic insights derived from routine clinical testing, complex anatomical pathology, and advanced molecular genomics [cite: 2, 3]. Quest annually serves one in three adult Americans and maintains commercial relationships with approximately half of the physicians and hospital systems across the United States [cite: 1].

The company generates revenue on a fee-for-service and volume-driven basis, billing commercial health plans, government health programs (Medicare and Medicaid), hospital organizations, employer enterprise clients, biopharmaceutical sponsors, and direct consumers [cite: 1, 2, 4]. Geographically, revenue is overwhelmingly derived from domestic operations across the United States, supplemented by expanding reference laboratory presence in select international markets including Canada [cite: 4, 5].

Core Products and Services

Quest offers a comprehensive diagnostic testing catalog exceeding 3,500 individual assays [cite: 1]. Its product portfolio is stratified into two operational pillars:
* Routine Clinical Testing: Standardized diagnostic panels including routine blood counts, metabolic profiles, lipid panels, urinalysis, immunodiagnostics, and toxicological screenings [cite: 2].
* Advanced Diagnostics: High-complexity testing spanning precision oncology (including Haystack MRD® liquid biopsy for minimal residual disease monitoring), neurology (such as AD-Detect® blood-based biomarkers for Alzheimer's disease), human genetics, infectious disease molecular testing, and complex cardiometabolic profiling [cite: 1, 3, 6].

Primary Customer Types and End Markets

Quest addresses four principal customer channels across the healthcare sector:
* Physicians and Outpatient Clinics: Independent physician practices, multispecialty medical groups, and outpatient care centers requiring outpatient clinical laboratory diagnostic services [cite: 1, 2, 4].
* Hospitals and Health Systems: Acute care hospitals and health systems utilizing Quest for reference laboratory testing, outreach laboratory management, and asset-light joint venture operations [cite: 1, 4, 6].
* Consumers: Individual health consumers accessing direct-to-consumer testing, wellness biomarker tracking, and digital health monitoring via questhealth.com and partner platforms [cite: 4, 6].
* Employers, Payors, and Life Sciences: Managed care organizations, self-insured corporate employers, and biopharmaceutical companies conducting clinical drug development trials [cite: 1, 2, 4].

Competitive Differentiation

Healthcare providers, payors, and patients choose Quest over alternative providers due to its nationwide logistics infrastructure, broad in-network coverage with major commercial payors, lower unit cost structure, and deep electronic health record (EHR) integrations [cite: 1, 6, 7]. In-network status minimizes out-of-pocket patient costs, while automated regional hub laboratories enable fast turnaround times for diagnostic results [cite: 1, 6, 7].

---

2. Business Drivers & Strategic Overview:

Quest Diagnostics operates at the confluence of clinical volume density, diagnostic complexity migration, and healthcare system consolidation [cite: 3, 4, 7]. The economic model relies heavily on volume leverage, as fixed courier logistics and laboratory automation generate operating margin expansion as requisition volumes increase [cite: 3, 7].

Business Driver / Strategic Pillar	Current Trajectory & Metrics	Strategic Context & Outlook
Requisition Volume Scale	+13.1% YoY in Q2 2026 (+13.0% organic) [cite: 3]	Core volume driven by demographic aging, chronic disease prevalence, and hospital outreach conversion [cite: 4, 7].
Revenue Per Requisition	-2.8% YoY in Q2 2026 [cite: 3]	Negative pricing mix offset by expanding volume in higher-value advanced molecular diagnostics [cite: 6, 7].
Health System Collaborations	Expanding joint ventures (Corewell Health, Fresenius) [cite: 4, 6]	Transitioning hospital outreach labs to low-capital joint venture models via Co-Lab Solutions [cite: 4, 6].
Consumer Health Segment	$250M baseline in 2025; >30% growth projected in 2026 [cite: 4]	High-margin digital sales via questhealth.com and digital health ecosystems (e.g., Function Health, Apple Health) [cite: 4, 6].
Advanced Diagnostics Expansion	Double-digit growth in oncology, neurology, cardiometabolic [cite: 6]	Shift toward proprietary precision medicine assays offsetting routine commodity price erosion [cite: 6, 7].

Comprehensive Moat Analysis

Quest maintains a durable competitive advantage driven by scale, logistics density, payor access, and digital integration:

• Scale and Unit Cost Leadership: Processing hundreds of millions of requisitions annually enables Quest to achieve lower fixed costs per test compared to hospital-based laboratories and regional independent labs [cite: 1, 3, 7]. Automated processing, high-throughput instruments, and optimized courier networks create structural cost efficiencies that encourage hospital outreach programs to outsource volume to Quest [cite: 1, 4, 7].
• Logistics Network and In-Network Payor Access: Quest operates more than 2,000 patient service centers nationwide, supplemented by thousands of in-office phlebotomists and an extensive intra-day courier system [cite: 1, 6]. This physical reach makes Quest an indispensable network provider for commercial health insurers seeking nationwide laboratory coverage for their beneficiaries [cite: 1, 2].
• High Switching Costs via Digital Workflows: Quest's laboratory information systems are integrated directly into physician EHR workflows and hospital ordering portals [cite: 6]. Replacing Quest requires clinical facilities to undergo disruptive IT reconfigurations, administrative retraining, and potential payor coverage mismatches [cite: 1, 2].

Total Addressable Market (TAM) Analysis

The domestic clinical laboratory testing market represents an addressable opportunity exceeding $100 Billion annually [cite: 4, 7]. Independent reference commercial laboratories currently control approximately 20% to 25% of total market revenue, with hospital internal and outreach laboratories accounting for 55% to 60%, and physician office labs holding the remaining share [cite: 1, 2, 4].

Primary expansion vectors within this market include:
* Hospital Outreach Outsourcing: A $30 Billion+ outreach market currently managed internally by health systems [cite: 4, 7]. Operating pressures and capital constraints are leading hospitals to monetize outreach operations through joint ventures or laboratory service acquisitions [cite: 4, 7].
* Consumer-Initiated Diagnostics: A expanding segment driven by personal health monitoring, growing at double-digit compound annual rates across direct-to-consumer digital channels [cite: 4, 6].
* Molecular Diagnostics and Precision Medicine: Oncology liquid biopsy, minimal residual disease (MRD) monitoring, and early neurological biomarker testing expanding the clinical scope and unit value of specialized testing [cite: 1, 6].

Competitive Landscape & Market Positioning

The national independent diagnostic testing industry is structured primarily as a co-duopoly between Quest Diagnostics and Labcorp Holdings Inc. [cite: 8, 9]. These two organizations maintain nationwide logistics networks and in-network payor coverage, holding a structural advantage over regional independent operators such as BioReference Health [cite: 8, 9].

In advanced molecular diagnostics, Quest competes with specialized testing providers including Exact Sciences, Natera, NeoGenomics, and Guardant Health [cite: 9, 10]. Quest’s strategy involves developing internal assays, forming strategic partnerships, or acquiring specialized companies (e.g., Haystack Oncology) and scaling those technologies across its established commercial infrastructure [cite: 1, 4, 6]. Quest continues to hold its core routine outpatient market share while capturing additional market share in hospital outreach and direct-to-consumer segments [cite: 4, 6, 8].

---

3. Financial Performance & Valuation:

Recent Financial Performance (Q2 2026)

Quest Diagnostics reported its second-quarter 2026 financial results on July 23, 2026, delivering top- and bottom-line expansion that exceeded consensus Wall Street projections [cite: 3, 11].

• Net Revenue: Consolidated revenue reached $3.043 Billion, representing a 10.2% increase compared to $2.761 Billion in Q2 2025 [cite: 3]. Organic revenue expanded 10.0%, driven by higher volume across physician, hospital, and consumer customer channels [cite: 3]. Total requisition volume grew 13.1% YoY (13.0% organic), while revenue per requisition declined 2.8% due to customer mix shifts and contractual pricing adjustments [cite: 3].
• Earnings Per Share (EPS): Reported diluted EPS was $2.84, an increase of 15.0% year-over-year [cite: 3]. Adjusted diluted EPS rose 19.1% YoY to $3.12, exceeding analyst consensus expectations of $2.82 by $0.30 per share (+10.64% earnings beat) [cite: 3, 11].
• Operating Margins: Reported operating income was $459 Million (15.1% of revenues) [cite: 3]. Adjusted operating income reached $502 Million, yielding an adjusted operating margin of 16.5% [cite: 3]. Adjusted operating margin moderated slightly by 40 basis points year-over-year, reflecting temporary integration costs from health system joint ventures (such as Corewell Health) offset by ongoing operational productivity savings [cite: 3, 6, 12].
• Cash Flow and Capital Deployment: Cash provided by operations reached $875 Million for the first six months of 2026 [cite: 3, 13]. Capital expenditures totaled $252 Million in the first half ($138 Million in Q2) [cite: 3, 13].

Full-Year Guidance Revision

In conjunction with Q2 2026 results, management raised its full-year 2026 financial outlook [cite: 3]:
* Full-Year 2026 Net Revenue: Increased to $11.95 Billion – $12.05 Billion [cite: 3].
* Full-Year 2026 Adjusted EPS: Raised to $11.05 – $11.25 [cite: 3].
* Capital Expenditures: Reaffirmed at approximately $550 Million [cite: 3].

Key Management Commentary

During executive presentations, management highlighted several key strategic themes [cite: 4, 6]:
1. Direct-to-Consumer Trajectory: Consumer health revenues through questhealth.com and commercial digital partnerships (Function Health, Hims & Hers, Apple Health) are on track to exceed 30% growth in 2026, generating operating margins above consolidated corporate averages [cite: 4, 6].
2. Advanced Diagnostics Adoption: Double-digit volume expansion in AD-Detect® blood tests for Alzheimer's disease assessment, advanced cardiometabolic/liver panels, and the commercial rollout of Haystack MRD® following New York State regulatory clearance [cite: 1, 6].
3. Health System Partnership Execution: Operational integration of the Corewell Health joint venture in Michigan and expanding renal laboratory services with Fresenius Medical Care validate the Co-Lab Solutions partnership framework [cite: 4, 6].

Stock Price Impact and Analyst Revisions

Following the July 23, 2026 earnings announcement, DGX shares rose 8.6% in the subsequent trading session [cite: 14]. Wall Street equity research analysts updated their outlooks: Barclays raised its price target to $260 (Overweight), Leerink increased its target to $265, and Truist reaffirmed its $260 price target [cite: 8].

Key Valuation Metric	Current Reported Level	Benchmark / Peer Comparison	Strategic Valuation Context
Share Price	$230.44 USD [cite: 14]	52-Week Range: $171.07 – $248.84 [cite: 8, 15]	Stock trades near the upper end of its annual channel [cite: 15, 16].
Market Capitalization	$25.6 Billion USD [cite: 14]	Enterprise Value: ~$31.2 Billion [cite: 14]	Large-cap market valuation [cite: 14, 16].
Forward P/E (FY2026E)	~20.4x [cite: 2]	Historical Range: 16.5x – 18.5x	Modest premium reflecting accelerated organic volume growth [cite: 2, 4].
EV / EBITDA (LTM)	~12.2x	Industry Peer Average: 11.5x – 13.5x	Valued in line with stable healthcare service providers [cite: 14].
Free Cash Flow Yield	~5.3% [cite: 14]	S&P 500 Average: ~4.0%	Cash flow generation supports dividend growth and repurchases [cite: 14, 17].
Dividend Yield	~1.5% [cite: 2]	Annual Dividend: $3.44 per share ($0.86/qtr) [cite: 8, 17]	Supported by 15 consecutive years of dividend increases [cite: 17].

The current valuation reflects investor expectations of organic revenue growth (4-5% CAGR), margin stability, and continued capital deployment through bolt-on acquisitions and share buybacks [cite: 7, 17].

---

4. Risk Assessment & Macroeconomic Considerations:

Company-Specific Execution Risks

• M&A and Health System Integration: Quest frequently acquires lab assets (e.g., LifeLabs) and establishes complex health system joint ventures [cite: 4, 5, 6]. Delays in IT consolidation, billing harmonization, or operational integration can temporarily elevate cost of services and press margins [cite: 3, 12].
• Cybersecurity and IT Infrastructure: Processing diagnostic testing requires secure IT platforms [cite: 1]. Cyber incidents, data breaches, or network outages could disrupt operational testing, expose the firm to legal liabilities, and damage customer trust [cite: 1].

Regulatory and Legal Risks

• Medicare Clinical Laboratory Fee Schedule (CLFS) Cuts: The primary regulatory risk stems from potential payment reductions under the Protecting Access to Medicare Act (PAMA) [cite: 8]. Preliminary proposal schedules from CMS include potential rate reductions of up to 15% on select high-volume routine test codes, which could create top-line headwinds starting in 2027 if fully implemented [cite: 8].
• FDA Oversight of Laboratory Developed Tests (LDTs): Potential expansion of FDA regulatory requirements for proprietary LDTs could increase compliance costs and lengthen development timelines for advanced diagnostic assays [cite: 6].

Macroeconomic Sensitivities & Industry Structure Risks

• Labor and Supply Chain Inflation: Phlebotomists, certified medical technologists, and logistics couriers constitute a core component of operating expenses [cite: 3, 12]. Sustained wage growth or elevated fuel costs directly affect cost of services [cite: 12].
• Outpatient Healthcare Utilization Trends: Requisition volumes are linked to outpatient physician office visits and hospital utilization [cite: 3, 12]. Economic downturns that result in job losses or shifts to higher-deductible health plans can lead patients to defer non-urgent diagnostic testing [cite: 12].

Risk Severity Analysis

• What Could Go Wrong: Unmitigated PAMA reimbursement cuts combined with sustained wage inflation could compress adjusted operating margins toward 13-14% [cite: 3, 8, 12].
• Early Warning Signs: Sequentially lower revenue per requisition that is not offset by advanced test volume growth, or operational margin compression within newly integrated health system joint ventures [cite: 3, 12].
• Long-Term Thesis Risk: Structural shifts in health system strategies away from laboratory outsourcing, or regulatory changes that reduce commercial reimbursement rates for molecular precision testing [cite: 4, 8].

---

5. 5-Year Scenario Analysis:

The 5-year valuation model projects Quest Diagnostics' performance through FY2031 across Base, High, and Low operational scenarios, using FY2026 baseline figures ($12.00 Billion revenue baseline; $230.44 USD current share price) [cite: 3, 14].

Financial Projection Methodology:

Net Income Year 5 = (Baseline Revenue * (1 + CAGR)^5) * Net Margin Year 5

EPS Year 5 = Net Income Year 5 / Diluted Shares Year 5

Implied Share Price Year 5 = EPS Year 5 * Exit P/E Multiple

Total Return = (Implied Share Price Year 5 + Cumulative Dividends - Current Share Price) / Current Share Price

Scenario Modeling Narrative

• Base Case: Organic requisition volume grows at 3.5% annually, supplemented by 2.0% annual revenue contributions from bolt-on acquisitions (total 5.5% top-line CAGR) [cite: 7]. Adjusted net profit margin stabilizes at 11.5% as laboratory automation offsets modest Medicare reimbursement cuts [cite: 3, 6]. Diluted share count decreases from 112 Million to 102 Million via ongoing share repurchases [cite: 3, 17]. An exit P/E multiple of 19.0x yields a Year 5 share price of $335.97 USD (+54.5% total return, 9.1% annualized return) [cite: 2, 14].
• High Case: Accelerated outsourcing by health systems, rapid expansion of direct-to-consumer testing (>30% CAGR), and widespread adoption of proprietary oncology and neurology assays drive an 8.0% revenue CAGR [cite: 1, 4, 6]. Scale benefits expand net margins to 12.8% [cite: 3, 4]. Diluted share count declines to 100 Million. An exit P/E multiple of 21.0x produces a Year 5 share price of $473.95 USD (+115.2% total return, 16.6% annualized return) [cite: 2].
• Low Case: PAMA reimbursement reductions lower pricing across routine testing, capping revenue CAGR at 2.5% [cite: 8]. Persistent wage inflation reduces net margins to 9.8% [cite: 3, 12]. Share repurchases slow, keeping share count at 106 Million. The market derates the stock to 15.0x P/E, resulting in a Year 5 share price of $188.28 USD (-10.5% total return, -2.2% annualized return) [cite: 14].

5-Year Share Price Trajectory Model (USD)

Metric	Baseline (FY2026)	Base Case (FY2031)	High Case (FY2031)	Low Case (FY2031)
Net Revenue (USD)	$12.00 Billion [cite: 3]	$15.68 Billion	$17.63 Billion	$13.58 Billion
5-Year Revenue CAGR	—	5.5%	8.0%	2.5%
Adjusted Net Margin	11.2% [cite: 3]	11.5%	12.8%	9.8%
Net Income (USD)	$1.34 Billion [cite: 14]	$1.80 Billion	$2.26 Billion	$1.33 Billion
Diluted Shares Outstanding	112 Million [cite: 3]	102 Million	100 Million	106 Million
Diluted EPS (USD)	$11.15 [cite: 3]	$17.68	$22.57	$12.55
Exit P/E Multiple	20.4x [cite: 2]	19.0x	21.0x	15.0x
Projected Share Price (USD)	$230.44 [cite: 14]	$335.97	$473.95	$188.28
Cumulative Dividends (USD)	—	$20.00	$22.00	$18.00
Total Return (%)	—	+54.5%	+115.2%	-10.5%
Annualized Return (%)	—	9.1%	16.6%	-2.2%

Scenario Summary Table

Scenario	Revenue / key scale metric in Year 5	Margin / earnings assumption	Valuation multiple assumption	Current share price	Implied future share price	5-year total return	Annualized return	Probability
Base Case	$15.68 Billion USD	11.5% Net Margin / EPS $17.68 USD	19.0x P/E	$230.44 USD	$335.97 USD	+54.5%	9.1%	55%
High Case	$17.63 Billion USD	12.8% Net Margin / EPS $22.57 USD	21.0x P/E	$230.44 USD	$473.95 USD	+115.2%	16.6%	25%
Low Case	$13.58 Billion USD	9.8% Net Margin / EPS $12.55 USD	15.0x P/E	$230.44 USD	$188.28 USD	-10.5%	-2.2%	20%

Probability-Weighted Target Price Calculation

Weighting the outcomes (55% Base Case, 25% High Case, 20% Low Case) yields a 5-year probability-weighted share price target of $340.92 USD, representing a probability-weighted 5-year total return of 56.8% inclusive of cash dividends.

RESILIENT CASH COMPOUNDER

---

6. Qualitative Scorecard:

Metric	Score (1-10)	Qualitative Evaluation & Strategic Assessment
Management Alignment	8 / 10	Executive compensation is tied 50% to revenue growth, 30% to ROIC, and 20% to relative TSR versus the S&P 500 Healthcare Index [cite: 17]. Management maintains a disciplined 10% ROIC hurdle rate after 3 years for M&A deployment [cite: 4].
Revenue Quality	8 / 10	High proportion of recurring revenue driven by routine, essential diagnostic testing across a broad payor base [cite: 1, 4]. Concentration in any single commercial customer is low [cite: 1].
Market Position	9 / 10	Commands co-duopoly leadership alongside Labcorp [cite: 8, 9]. Scale, patient service center density, and deep physician EHR integrations create high barriers to competitive entry [cite: 1, 6].
Growth Outlook	7 / 10	Core volume grows 2-3% driven by demographic aging [cite: 4, 7]. Faster-growing consumer diagnostics and advanced oncology testing elevate consolidated growth potential to 5-8% annually [cite: 4, 6, 7].
Financial Health	8 / 10	Solid balance sheet backed by annual operating cash flows exceeding $1.6 Billion and a manageable net debt footprint (~$5.64 Billion total debt vs. $25.6 Billion market cap) [cite: 3, 13, 14].
Business Viability	9 / 10	Laboratory diagnostics inform over 70% of clinical healthcare decisions, establishing Quest as an enduring core component of the U.S. healthcare delivery framework [cite: 1].
Capital Allocation	8 / 10	Disciplined framework balancing steady dividend growth ($3.44 annual rate), opportunistic share buybacks ($450M+ in 2025), and bolt-on acquisitions meeting hurdle rates [cite: 4, 17].
Analyst Sentiment	8 / 10	Analyst consensus is constructive following consecutive quarterly earnings beats, with major brokerages raising price targets into the $260–$265 range [cite: 8].
Profitability	8 / 10	Robust profitability profile generating ~16.5% adjusted operating margins and an ROE of 14.6% [cite: 2, 3]. Laboratory automation continues to support operating leverage [cite: 6, 7].
Track Record	8 / 10	Proven history of shareholder returns, outperforming the S&P 500 Healthcare Index over multi-year periods while maintaining 15 consecutive years of dividend growth [cite: 17].

Blended Qualitative Score: 8.1 / 10

WIDE ECONOMIC MOAT

---

7. Conclusion & Investment Thesis:

Quest Diagnostics maintains a strong market position as a core service provider within the U.S. healthcare system [cite: 1, 2]. The operational investment case is supported by three primary factors:

1. Consolidation Advantages: Quest’s lower cost structure positions it to capture hospital outreach volumes through laboratory acquisitions, outsourcing agreements, and joint ventures (such as Corewell Health) [cite: 1, 4, 6].
2. Product Mix Shift Toward Advanced Testing: Growth in advanced oncology diagnostics (Haystack MRD®), neurological biomarkers (AD-Detect®), and direct-to-consumer health channels increases revenue per test and supports corporate margins [cite: 1, 4, 6].
3. Cash Flow Deployment: Strong free cash flow generation (~5.3% FCF yield) enables regular capital return to shareholders through dividends and share buybacks alongside strategic M&A investments [cite: 3, 4, 14, 17].

These growth drivers are offset by potential reimbursement reductions under Medicare's PAMA fee schedules [cite: 8]. However, Quest’s scale, automation investments, and expansion into non-regulated direct consumer diagnostic channels help insulate the long-term business model [cite: 4, 6, 7].

DEFENSIVE HEALTHCARE COMPOUNDER

---

8. Technical Analysis, Price Action & Short-Term Outlook:

Quest Diagnostics (DGX) trades around $230.44 USD, positioned above its 200-day simple moving average ($206.08 USD) and slightly below its 50-day moving average ($235.70 USD) [cite: 14, 16, 18]. The stock has appreciated ~26.5% year-to-date, consolidating near the upper end of its 52-week channel ($171.07 to $248.84 USD) [cite: 8, 15]. Technical indicators reflect neutral short-term momentum (14-day RSI of 56.26) following positive price action after Q2 earnings [cite: 14, 16]. Near-term share performance is expected to remain within a range of $225 to $245 USD as market participants monitor upcoming Q3 results and CMS reimbursement updates [cite: 8].

NEUTRAL SHORT TERM

---

1. Quest Diagnostics - Investor Relations, https://ir.questdiagnostics.com/overview/default.aspx
2. Quest Diagnostics (DGX) Stock Analysis: Navigating The Diagnostic Giant's Investment Landscape - DirectorsTalk Interviews, https://www.directorstalkinterviews.com/quest-diagnostics-dgx-stock-analysis-navigating-the-diagnostic-giants-investment-landscape/4121263208
3. Financial Info - Quarterly Results - Quest Diagnostics - Investor Relations, https://ir.questdiagnostics.com/financial-info/quarterly-results/default.aspx
4. Quest Diagnostics (DGX) Investor Relations, Earnings Summary & Outlook - Quartr, https://quartr.com/companies/quest-diagnostics-inc_3577
5. Earnings call: Quest Diagnostics reports robust Q3 growth, eyes M&A, https://www.investing.com/news/stock-market-news/earnings-call-quest-diagnostics-reports-robust-q3-growth-eyes-ma-93CH-3675952
6. Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026 - PR Newswire, https://www.prnewswire.com/news-releases/quest-diagnostics-reports-second-quarter-2026-financial-results-raises-revenue-and-eps-guidance-for-full-year-2026-302832675.html
7. Quest Diagnostics to Highlight Strategic Priorities to Drive Sustainable Growth and Deliver Long-term Shareholder Value at 2025 Investor Day, https://ir.questdiagnostics.com/press-releases/press-release-details/2025/Quest-Diagnostics-to-Highlight-Strategic-Priorities-to-Drive-Sustainable-Growth-and-Deliver-Long-term-Shareholder-Value-at-2025-Investor-Day/default.aspx
8. Quest Diagnostics Incorporated Stock Price: Quote, Forecast, Splits & News (DGX) - Perplexity, https://www.perplexity.ai/finance/DGX?comparing=DGX,LH,DHR,MTD,TMO,ICLR
9. 10-K: Annual report [Section 13 and 15(d), not S-K Item 405] | NeoGenomics, Inc. (NEO), https://ir.neogenomics.com/sec-filings/all-sec-filings/content/0001077183-26-000010/neo-20251231.htm
10. 073 - Exact Sciences 2024 Financial Statements 10-K.pdf - Oregon.gov, https://www.oregon.gov/oha/HPA/HP/HCMOPageDocs/073%20-%20Exact%20Sciences%202024%20Financial%20Statements%2010-K.pdf
11. Quest Diagnostics (DGX) Earnings: Latest Report, Earnings Call & Financials, https://public.com/stocks/dgx/earnings
12. Quest Diagnostics (DGX) Earnings Call Transcripts | Gloomberb, https://gloom.sh/stocks/dgx/transcripts
13. Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026, https://ir.questdiagnostics.com/press-releases/press-release-details/2026/Quest-Diagnostics-Reports-Second-Quarter-2026-Financial-Results-Raises-Revenue-and-EPS-Guidance-for-Full-Year-2026/default.aspx
14. Quest Diagnostics (DGX) - Trefis, https://www.trefis.com/data/companies/DGX
15. Is Quest Diagnostics Incorporated a Good Stock to Buy in October 2026 - NAGA, https://naga.com/en/instruments/DGX.re
16. Quest Diagnostics (DGX) Stock Report: Evaluating A Potential 6.17% Upside In The Diagnostics Giant - DirectorsTalk Interviews, https://www.directorstalkinterviews.com/quest-diagnostics-dgx-stock-report-evaluating-a-potential-6-17-upside-in-the-diagnostics-giant/4121265373
17. Quest Diagnostics - SEC.gov, https://www.sec.gov/Archives/edgar/data/1022079/000114036126013356/ny20064122x1_def14a.htm
18. Quest Diagnostics (DGX) Stock Analysis: A Diagnostic Powerhouse With Steady Growth Potential - DirectorsTalk Interviews, https://www.directorstalkinterviews.com/quest-diagnostics-dgx-stock-analysis-a-diagnostic-powerhouse-with-steady-growth-potential/4121264254